Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 8/20 | 0.87 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.87 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.60 |
| ▸ | NCF1 | P14598 | 1/20 | 0.60 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.59 |
| ▸ | HTR3B | O95264 | 1/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.59 |
| ▸ | HTR3A | P46098 | 1/20 | 0.59 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.59 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.56 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5335 | 1.00 | CHRNB2 (0.87) | CHRNB2CHRNA4ADRB2NCF1PLD1 | |
| SCHEMBL3538787 | 1.00 | CHRNB2 (0.87) | CHRNB2CHRNA4ADRB2NCF1PLD1 | |
| Hydrochloric Acid SCHEMBL9066315 | 0.98 | CHRNB2 (0.84) | CHRNB2CHRNA4ADRB2NCF1PLD1 | |
| SCHEMBL3061045 | 0.93 | CHRNB2 (1.00) | CHRNB2CHRNA4ADRB2NCF1PLD1 | |
| SCHEMBL6350076 | 0.92 | CHRNB2 (0.91) | CHRNB2CHRNA4ADRB2NCF1PLD1 | |
| SCHEMBL3065598 | 0.90 | CHRNB2 (0.94) | CHRNB2CHRNA4ALDH1A1CHRNA7CHRNB4 | |
| SCHEMBL5171064 | 0.89 | CHRNB2 (0.71) | CHRNB2CHRNA4ALDH1A1CHRNA7CHRNB4 | |
| SCHEMBL5655866 | 0.89 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL28210749 | 0.86 | CHRNB2 (0.67) | CHRNB2CHRNA4ADRB2NCF1PLD1 | |
| Fumaric Acid SCHEMBL27454231 | 0.86 | CHRNB2 (0.67) | CHRNB2CHRNA4ADRB2NCF1PLD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116924976-A | Diaryl heterocyclic amine compound, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2023-10-24 | — | — | CN | claimed |
| CN-114806414-B | Silicon polishing composition, preparation method and application thereof | 万华化学集团电子材料有限公司 | 2023-07-11 | — | — | CN | claimed |
| CN-114806414-A | Silicon polishing composition, preparation method and application thereof | 万华化学集团电子材料有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-114245753-A | Combination of an anti-HER 2 antibody and a CDK inhibitor for tumor therapy | 江苏康宁杰瑞生物制药有限公司 | 2022-03-25 | — | — | CN | claimed |
| EP-4743446-A1 | NITRO-CONTAINING COMPOUNDS THAT KILL MYCOBACTERIA | Board of Trustees of Michigan State University (US) | 2026-05-20 | — | — | EP | disclosed |
| CN-122059950-A | Compounds with proteasome agonistic activity, preparation method and application thereof | 浙大城市学院 | 2026-05-19 | — | — | CN | disclosed |
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739684-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-20260078114-A1 | COMPOUND USED AS INHIBITOR OF CDK4 KINASE AND USE THEREOF | TYK MEDICINES INC (CN) | 2026-03-19 | — | — | US | disclosed |
| CN-121574100-A | Aminopyrimidine derivative and preparation method and application thereof | 天津市肿瘤医院（天津医科大学肿瘤医院） | 2026-02-27 | — | — | CN | disclosed |
| US-20260014160-A1 | G1T38 SUPERIOR DOSAGE REGIMES | PHARMACOSMOS HOLDING A/S (DK) | 2026-01-15 | — | — | US | disclosed |
| US-20250345342-A1 | METHODS FOR THE TREATMENT OF CANCER USING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA | CELCUITY INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-20220362254-A1 | METHODS FOR REPROGRAMMING CANCER CELLS | UNIV JEFFERSON (US) | 2022-11-17 | — | — | US | disclosed |
| US-20220354845-A1 | METHODS FOR ENHANCING DNA DAMAGE AND APOPTOSIS OF LEUKEMIC CELLS | UNIV JEFFERSON (US) | 2022-11-10 | — | — | US | disclosed |
| US-11446295-B2 | Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors | G1 THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220267315-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2022-08-25 | — | — | US | disclosed |
| CN-114806414-A | Silicon polishing composition, preparation method and application thereof | 万华化学集团电子材料有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-20220194961-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. | 2022-06-23 | — | — | US | disclosed |
| US-11357779-B2 | G1T38 superior dosage regimes | G1 THERAPEUTICS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20220175780-A1 | TREATMENT OF RB-NEGATIVE TUMORS USING TOPOISOMERASE INHIBITORS IN COMBINATION WITH CYCLIN DEPENDENT KINASE 4/6 INHIBITORS | PHARMACOSMOS A/S (DK) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014160-A1 | G1T38 SUPERIOR DOSAGE REGIMES | CDK4, CCND1, CDK8 | CHRNB2 4644/4885CHRNA4 4085/4885ADRB2 4407/4885 |
| US-20260078114-A1 | COMPOUND USED AS INHIBITOR OF CDK4 KINASE AND USE THEREOF | CDK4, CDK1, CDK3 | CHRNB2 2632/4885CHRNA4 2286/4885ADRB2 3026/4885 |
| US-11446295-B2 | Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors | CDK4, RB1, BTK | CHRNB2 4639/4885CHRNA4 4673/4885ADRB2 4804/4885 |
| US-20220175780-A1 | TREATMENT OF RB-NEGATIVE TUMORS USING TOPOISOMERASE INHIBITORS IN COMBINATION WITH CYCLIN DEPENDENT KINASE 4/6 INHIBITORS | RB1, CDK4, CDK6 | CHRNB2 4420/4885CHRNA4 4014/4885ADRB2 4740/4885 |
| US-11357779-B2 | G1T38 superior dosage regimes | CXCL8, ELANE, CD4 | CHRNB2 2536/4885CHRNA4 3273/4885ADRB2 3679/4885 |
| US-20220194961-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | CHRNB2 4879/4885CHRNA4 4869/4885ADRB2 4827/4885 |
| US-20250345342-A1 | METHODS FOR THE TREATMENT OF CANCER USING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA | CDK4, CDKN1A, CDK2 | CHRNB2 4856/4885CHRNA4 4729/4885ADRB2 4448/4885 |
| US-20220267315-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | CDK4, CDK6, CDK3 | CHRNB2 3552/4885CHRNA4 3303/4885ADRB2 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.